1. Inicio
  2. Publicaciones
  3. Impact of Cytogenetic Risk on Outcomes of Non-T Cell Depleted Haploidentical Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia.

Impact of Cytogenetic Risk on Outcomes of Non-T Cell Depleted Haploidentical Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Nagler, Arnon
  • Labopin, Myriam
  • Dholaria, Bhagirathbhai
  • Ciceri, Fabio
  • Fraccaroli, Alessia
  • Blaise, Didier
  • Fanin, Renato
  • Bruno, Benedetto
  • Forcade, Edouard
  • Vydra, Jan
  • Chevallier, Patrice
  • Bulabois, Claude Eric
  • Jindra, Pavel
  • Bornhauser, Martin
  • Canaani, Jonathan
  • Savani, Bipin N.
  • Spyridonidis, Alexandros
  • Giebel, Sebastian
  • Brissot, Eolia
  • Bazarbachi, Ali
  • Esteve, Jordi
  • Mohty, Mohamad

Grupos

Abstract

Baseline cytogenetics and disease status are key factors predicting the outcomes of allogeneic hematopoietic cell transplantation (HCT) in patients with acute myeloid leukemia (AML). The importance of cytogenetic risk in patients with primary refractory or relapsed (R/R) AML undergoing haploidentical (Haplo) HCT is unknown. We studied the impact of cytogenetic risk in patients with R/R de novo AML with active disease who underwent non-T-cell-depleted Haplo-HCT with post-transplantation cyclophosphamide from 2010 to 2020. Four hundred forty patients with active disease at transplantation from the European Society for Blood and Marrow Transplantation database were analyzed (291 [66.1%] with intermediate-risk [AMLint] and 149 [44.1%] with adverse-risk cytogenetics [AMLadv]). Impact of baseline cytogenetic risk on various transplantation outcomes was evaluated. Pre-transplantation disease status was relapse in 48.1% and 26.8% and primary refractory in 51.9% and 73.2% of the patients with AMLint and AMLadv, respectively (P < .0001). Two-year leukemia-free survival (LFS, 35.5% versus 15.5%, P=.001) and overall survival (OS, 39.2% versus 20.1%, P=.001) were better in AMLint versus AMLadv. In multivariate analysis, the relapse rate was significantly higher (hazard ratio [HR]=2.17 [95% confidence interval {CI} 1.57-3.0]) and LFS (HR=1.71 [95% CI, 1.31-2.22]) and OS (HR=1.69 [95% CI, 1.29-2.22]), significantly lower for patients with AMLadv compared to AMLint, conditioning intensity did not affect leukemia relapse rate. Non-relapse mortality (HR=1.1 [95% CI, 0.7-1.74]) and graft-versus-host disease-free, relapse-free survival (HR=1.37 [95% CI, 1.06-1.77]) did not differ significantly between the risk groups. Disease status before transplant (primary refractory versus relapsed) or conditioning intensity did not impact main transplant outcomes. Baseline cytogenetic risk remains a key prognostic factor for patients with R/R AML with persistent disease before non-T-cell-depleted Haplo-HCT.

Copyright © 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Datos de la publicación

ISSN/ISSNe:
2666-6375, 2666-6367

Transplantation and Cellular Therapy  ELSEVIER SCIENCE INC

Tipo:
Article
Páginas:
7731-7738
PubMed:
36031079
Enlace a otro recurso:
www.scopus.com

Citas Recibidas en Web of Science: 8

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Acute myeloid leukemia; Allogeneic stem cell transplantation; Cytogenetic risk; Haploidentical; Post-transplant cyclophosphamide; Relapse

Campos de Estudio

Cita

Compartir